NRx Pharmaceuticals, Inc. (NRXP) is a clinical-stage biopharmaceutical company, not an ETF, focused on central nervous system (CNS) disorders such as suicidal bipolar depression, PTSD, and chronic pain. Five current, attributable analyst targets were reviewed to establish the central target. Ascendiant maintained a Buy with a $50 target, H.C. Wainwright analyst Patrick Trucchio reiterated a Buy with a $45 target, Lucid Capital initiated coverage with a $49 target, D. Boral Capital maintained a $34 target, and BTIG analyst Thomas Shrader maintained a $10 target.
That yields a range of $10 to $50 and an arithmetic mean of roughly $37.60, rounded to a clean $38 central target. The spread between the $10 low and the $50 high is dramatic and signals genuine uncertainty about whether NRx's pipeline translates into commercial products. None of these figures should be read as a guarantee; they are individual analyst opinions tied to a roughly 12-month research horizon, and they differ sharply on how much value to assign to an unapproved drug portfolio.
The latest verified price for NRXP is approximately $2.69, giving the company a market capitalization of roughly $110 million to $117 million. Reaching the $38 central target would require an advance of about 1,310%, a very large move by any standard and one that essentially implies successful drug approvals and commercial ramp rather than incremental progress. The stock has traded between about $1.62 and $5.06 over the past 52 weeks, so a move toward even the low end of the analyst range would represent a multi-fold re-rating.
The path toward a higher valuation runs through regulatory milestones. NRx is advancing an ANDA (Abbreviated New Drug Application) for preservative-free ketamine and an NDA (New Drug Application) for NRX-100, its IV ketamine candidate for suicidal depression, with a GDUFA goal date of November 10, 2026. The company has also reported a Phase 2/3 trial of NRX-101 combined with robotic TMS (transcranial magnetic stimulation). Any target at $38 depends heavily on these programs producing positive clinical and regulatory outcomes.
Several verified developments underpin the bullish analyst targets. NRX-101 holds FDA Breakthrough Therapy designation for suicidal treatment-resistant bipolar depression, and NRX-100 has Fast Track designation. In October 2026 the company announced an $11.18 million DARPA prime contract to evaluate robotic magnetic stimulation combined with NRX-101, along with completion of FDA process validation and two-year stability data for preservative-free ketamine. The company has also reported a first-cycle FDA review of its ketamine ANDA with no drug-related major deficiencies.
Financially, net losses narrowed in the first half of 2026, and cash of about $26.7 million as of June 30, 2026 was supported by a public offering with gross proceeds above $22 million. The potential addressable markets, including treatment-resistant depression estimated in the millions of patients, give analysts a basis for projecting significant upside if approvals arrive.
The risks are equally concrete. NRx remains unprofitable, with limited cash and a history of dilutive financing. Approval timelines can slip, and an unfavorable FDA decision on the ketamine ANDA or NRX-100 NDA would undercut the central case. The wide analyst range, including a $10 target, reflects the possibility that the company's assets generate far less value than the most optimistic projections. Competition in depression and ketamine-based therapies, reliance on real-world evidence for regulatory support, and the execution risk of expanding the HOPE Therapeutics clinic network are additional obstacles. A move to $38 would also require sustained investor confidence through multiple binary clinical and regulatory events.
From a technical standpoint, NRXP trades well below its 52-week high near $5.06 and only modestly above its 52-week low near $1.62. The $2.50 area has functioned as a nearby reference level, while the prior high around $5 serves as the first meaningful resistance zone above the current price. Given the magnitude of the target, conventional support and resistance levels offer limited guidance; the stock's trajectory is driven primarily by news flow and regulatory catalysts rather than chart structure.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms may use different timeframes. Investors should watch the November 10, 2026 GDUFA goal date for preservative-free ketamine, further progress on the NRX-100 NDA and the NRX-101 NDA filing, enrollment and data from the MIND1 and SPARC-TMS trials, quarterly cash and net-loss figures, any additional financing, and analyst target revisions. Regulatory decisions on ketamine and NRX-101 are the clearest near-term catalysts that could reshape the outlook in either direction.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review alone. For investors tracking NRXP through its volatile clinical milestones, an automated, data-driven signal layer can complement fundamental research and help flag momentum changes as they develop.
Can NRXP reach $38? The target represents the arithmetic mean of five analyst price targets ranging from $10 to $50, and it sits more than 1,300% above the current price of roughly $2.69. Reaching it would require successful regulatory approvals, meaningful commercial traction, and a sustained re-rating that turns a clinical-stage micro-cap into a revenue-generating pharmaceutical company. Positive FDA milestones, Breakthrough and Fast Track designations, and the DARPA contract provide genuine support, but limited cash, continuing losses, dilutive financing, and the binary nature of pending regulatory decisions are substantial obstacles. With analysts themselves spread from $10 to $50, the path is highly uncertain, and investors should focus next on the November 2026 FDA goal date and upcoming clinical and financial updates rather than any single price level.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NRXP has been closely correlated with TAOX. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if NRXP jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To NRXP | 1D Price Change % | ||
|---|---|---|---|---|
| NRXP | 100% | +2.41% | ||
| TAOX - NRXP | 84% Closely correlated | -3.63% | ||
| ALLR - NRXP | 81% Closely correlated | +5.74% | ||
| PALI - NRXP | 74% Closely correlated | -7.52% | ||
| COYA - NRXP | 34% Loosely correlated | +0.25% | ||
| ACET - NRXP | 33% Loosely correlated | -1.25% | ||
More | ||||